{"brief_title": "A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma", "brief_summary": "To estimate the response rate, response duration, clinical benefit, and toxicity of mitoguazone dihydrochloride (MGBG) in patients with AIDS-related refractory or relapsing non-Hodgkin's lymphoma (NHL).", "detailed_description": "Patients receive infusions of MGBG on days 1 and 8 and every 2 weeks thereafter. It is suggested that a lumbar puncture be performed to evaluate for leptomeningeal disease.", "condition": ["Lymphoma, Non-Hodgkin", "HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Mitoguazone"], "criteria": "Inclusion Criteria Patients must have: - HIV positivity by ELISA confirmed by Western blot. - AIDS-related NHL that is refractory or relapsed. - Life expectancy of at least 12 weeks. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - Concomitant malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or non-active, non-visceral Kaposi's sarcoma not requiring active chemotherapy. - Active uncontrolled bacterial infection, viral infection (other than herpes simplex), or fungal infection (other than oropharyngeal candidiasis) that requires treatment within 2 weeks of study entry. - Significant cardiovascular disease. Concurrent Medication: Excluded: - Hormonal therapy (except medications given for muscle wasting, such as testosterone or Megace). - Other chemotherapy. - Investigational anti-cancer drugs. Concurrent Treatment: Excluded: - Concomitant radiation to sites other than CNS. Patients with the following prior conditions are excluded: Prior malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or non-active, non-visceral Kaposi's sarcoma not requiring active chemotherapy. Recommended: - Prophylaxis for PCP and oral candidiasis. Required in patients with leptomeningeal disease: - Intrathecal methotrexate or cytarabine (Ara-C). - Leucovorin. Required in patients with leptomeningeal disease: Cranial radiation to a helmet field.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Mitoguazone", "mesh_term": ["Lymphoma", "HIV Infections", "Lymphoma, Non-Hodgkin", "Immunologic Deficiency Syndromes", "Acquired Immunodeficiency Syndrome", "Mitoguazone"], "id": "NCT00002348"}